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Finding the Missing Pieces: Comprehensive Cerebellar Assessments with Cytarabine Administration
CASE STUDY:
Stan (name changed for confidentiality) was a 60 year old male admitted to the hospital with relapsed AML in the
summer of 2015 after two years of remission. Stan was first diagnosed three years earlier and subsequently underwent
chemotherapy and stem cell transplant with no known neurotoxicity. In 2015, re-induction chemotherapy 7 + 3 with
Idarubicin and Cytarabine was completed in the hospital. Prior to treatment, Stan was walking independently with no
functional deficits. Current standard of practice at the St. Cloud Hospital for cerebellar monitoring included having the
patient sign his/her name daily.
▪ Day 1 Post Chemo at 0800: Patient reported increased bilateral lower extremity weakness with walking. IV fluids
were initiated. No deficits noted in signing of the name.
▪ Day 1 Post Chemo at 2300: Patient is now unable to void, requiring ongoing straight catheterizations. Stan reports
inability to walk, has significant decreased sensations in bilateral lower extremities. Still able to sign his name
without deficits noted.
▪ Day 2 Post Chemo at 0800: Neurology consulted. Stan reports weakness has reached his bilateral upper
extremities. MRI of lumbar, thoracic, cervical and head all negative. Findings all suggest acute paraplegia and
painful peripheral neuropathy as a result of acute cytarabine neurotoxicity.
▪ Within several weeks of ongoing therapy, patient had regained all bowel/bladder function and most function and
strength in bilateral upper and lower extremities.

DISCUSSION:

COMPONENTS OF A COMPREHENSIVE ASSESSMENT
▪ Nurses need to have the means to accurately and consistently assess and document neurological changes noted with Cytarabine administration. The
assessment tool must be comprehensive, covering several areas of cerebellum function. Assessments should be completed every shift and/or prior to
each dose of cytarabine (Brown & Hall, 2010) (O’Leary, 2004).
▪ The initial assessment and first dose of High-Dose Cytarabine should be completed during the day time hours to promote patient satisfaction and ensure
accuracy of assessment (Szoch & Kaiser, 2015).
▪ The assessment should be relatively short in time (approximately 5-10 minutes or less); especially with the increased demands placed on hospital-based
nursing care. Tool should be easy to understand for nurses at all skill levels and integrated into current charting practice (Brown, 2010).
▪ If the patient fails any aspect of the assessment, the upcoming dose should be held and the oncologist notified immediately. If the patient is to receive
medications that may alter gross motor skills, such as narcotics, a cerebellar assessment should be completed prior to administration to ensure accuracy
of the assessment (O’Leary, 2004).
▪ Crucial components of cerebral and cerebellar functional assessments include: (Brown, 2010) (Szoch & Kaiser, 2015)
Gait and balance: Watch for signs of arrhythmia or asymmetry. This is best completed by patient walking heel to toe in straight line.
Handwriting: Most often monitored by signing his/her name; preference to utilize a skill that usually doesn’t change over time.

▪ There were several unknown variables to explain why Stan experienced probable neurotoxicity with non-high dose
therapy. No data was available regarding therapies received prior to transplant. There is a possibility the patient had
exceeded the recommended lifetime dose limit and/or had a previous neurotoxic reaction in the past, making him more
susceptible.
▪ The case was discussed with Kathleen Rieke, MD of Neurology. Dr. Rieke recommends any patients receiving
Cytarabine in ANY strength be assessed for neurotoxicity, including assessment of motor strength and function of
all four extremities every shift.

Speech Pattern: Have patient state name, date, time, and situation.
Body Tremors: Monitor for tremors while standing or walking.
Nystagmus: When present, this will cause involuntary rapid eye movement when attempting to focus on an object.
Point – to – Point Testing: Patient’s finger directly makes contact with observer’s finger and his/her own nose several times as observer
moves throughout patient’s vision field.

WHAT IS CYTARABINE?
Cytarabine (Ara-C) is an anti-metabolite chemotherapy agent used to treat
acute leukemia and/or refractory non-hodgkin’s lymphoma . The drug
is cell-cycle specific and inhibits DNA synthesis thus halting cell division.
The dose-limiting toxicity of this drug is NEUROTOXICITY, especially
when given in high-dose concentration (Szoch & Kaiser, 2015). This is
caused by a widespread loss of Purkinje cells in the cerebellum (Lee &
Wen, 2015). With high-dose cytarabine administration, there is a high
concentration of drug that crosses the blood-brain barrier in the cerebral
spinal fluid with 50% of the chemotherapy still in the plasma
concentration (O’Leary, 2004).

WHEN IT BECOMES NEUROTOXIC
▪ Patient’s receiving high-dose cytarabine have a 7-28% incidence of
developing neurotoxicity; high doses include ≥ 1-3g/m² (Lee & Wen,
2015).
▪ 10-25% of patient’s develop neurotoxicity when the cumulative dose
exceeds 30 grams in a lifetime (Lee & Wen, 2015).
▪ There is a 60% incidence of cerebellar toxicity reoccurrence for
patient’s who showed previous toxicity (O’Leary, 2004).
▪ Other risk factors include decreased hepatic and/or renal dysfunction
and/or age >60 years old (Szoch & Kaiser, 2015).
▪ Symptoms usually develop 2-8 days after initial dose and may persist 310 days after discontinuation of therapy (O’Leary, 2004).
▪ For those >50 years old, symptoms may persist for more than 30 days
even if therapy is stopped (O’Leary, 2004).
▪ Up to 30% of patients may not regain normal cerebellar function
(O’Leary, 2004).
▪ Symptoms include gait and balance disturbances, alterations in fine
motor skills, memory loss, peripheral neuropathy and/or seizures (Lee
& Wen, 2015).
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NURSING
CONSIDERATIONS
A study conducted at the
University of Maryland
Greenebaum Cancer Center found
that one in four nurses felt there were
widespread inconsistencies with
cerebellar assessments. One of every
two nurses felt the current assessment
was incomplete and the patient may
be suffering as a result.
(Szoch & Kaiser, 2015)
There has to be a better way!

Rapid alternating hand movements: Patient will pat hands on thighs in rhythmic motion as fast as possible without losing
coordination.
Romberg Test: Measures three sensory systems in cerebellum to maintain stability, including vision, proprioception and vestibular sense.
To complete successfully, patient will stand with feet together and eyes closed for 5-10 seconds.
(Brown, 2010) (Szoch & Kaiser, 2015)

SAMPLES OF ASSESSMENT TOOLS
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